Theriva Biologics (TOVX) Preferred Stock Liabilities (2017 - 2024)
Theriva Biologics (TOVX) posted quarterly Preferred Stock Liabilities of $728000.0 for Q2 2024, down 63.71% year-over-year from $2.0 million in Q3 2023, and little changed quarter-over-quarter from $728000.0 in Q1 2024.
Theriva Biologics (TOVX) Preferred Stock Liabilities (2017 - 2024) Analysis & Trends
Theriva Biologics (TOVX) has reported Preferred Stock Liabilities for 7 consecutive years, with $728000.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Preferred Stock Liabilities fell 63.71% year-over-year to $728000.0; the TTM figure through Jun 2024 stood at $728000.0 (down 63.71% YoY), while the FY2023 annual figure was $728000.0, down 63.71% from the prior year.
- Preferred Stock Liabilities held at $728000.0 in Q2 2024 per TOVX's latest filing, from $728000.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $12.8 million in Q4 2020 and bottomed at $728000.0 in Q4 2023.
- Historically, Preferred Stock Liabilities has averaged $5.3 million across 4 years, with a median of $2.0 million in 2022.
- Annual changes were most pronounced in 2020 — Preferred Stock Liabilities gained 2.02% — and 2023, when it slumped 63.71%.
- Theriva Biologics' Preferred Stock Liabilities stood at $12.8 million in 2020, then tumbled by 84.33% to $2.0 million in 2022, then plunged by 63.71% to $728000.0 in 2023, then changed by 0.0% to $728000.0 in 2024.
- Business Quant data shows TOVX's Preferred Stock Liabilities at $728000.0 in Q2 2024, $728000.0 in Q1 2024, and $728000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 728,000.00 |
| Mar 31, 2024 | 728,000.00 |
| Dec 31, 2023 | 728,000.00 |
| Sep 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | 2.01 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 2.01 Mn |
| Sep 30, 2022 | 2.01 Mn |
| Dec 31, 2020 | 12.80 Mn |
| Sep 30, 2020 | 12.73 Mn |
| Jun 30, 2020 | 12.67 Mn |
| Mar 31, 2020 | 12.61 Mn |
| Dec 31, 2019 | 12.54 Mn |
| Sep 30, 2019 | 12.48 Mn |
| Jun 30, 2019 | 12.42 Mn |
| Mar 31, 2019 | 12.36 Mn |
| Dec 31, 2018 | 12.30 Mn |
| Sep 30, 2018 | 12.23 Mn |
| Jun 30, 2018 | 12.17 Mn |
| Mar 31, 2018 | 12.11 Mn |